MA
DRNA

MUFG Americas’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

MUFG Americas’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-130
Closed -$2K – 1258
2015
Q2 		$2K Buy
+130
New +$2.38K ﹤0.01% 1109

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

MUFG Americas's DRNA Position: Q3 2015 in Review

MUFG Americas sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2015, closing a stake of 130 shares — an estimated $2K sold.

MUFG Americas first reported a position in DRNA in Q2 2015 and held it in 1 quarter. The position peaked at $2K in Q2 2015. 51 funds tracked by Wall St. Rank hold DRNA as of Q3 2015.

  • MUFG Americas reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • MUFG Americas sold 130 Dicerna Pharmaceuticals, Inc. shares in Q3 2015, an estimated $2K.
  • MUFG Americas first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • MUFG Americas's Dicerna Pharmaceuticals, Inc. position peaked at $2K in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2015.

Based on MUFG Americas's 13F filing for Q3 2015, filed 10 Nov 2015.